First European Union Patient Dosed with 177Lu-PNT2002 in the Phase 3 SPLASH Trial
26 avr. 2022 08h30 HE
|
POINT Biopharma
POINT Biopharma’s Phase 3 SPLASH trial in pre-chemo metastatic castration-resistant prostate cancer (mCRPC) is now randomizing in the US, Canada, and Europe Sites initiated in France, Sweden,...
QSAM Biosciences Receives Japanese Patent for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam®
12 avr. 2022 08h00 HE
|
QSAM Biosciences Inc.
Austin, TX, April 12, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
POINT Biopharma to Present on its Pan-Cancer FAP-Alpha Targeted Program at the AACR Annual Meeting
11 avr. 2022 16h30 HE
|
POINT Biopharma
POINT’s PNT6555 is a potent and specific inhibitor of Fibroblast Activation Protein (FAP), a phase 1 therapeutic trial using 68Ga-PNT6555 for imaging and 177Lu-PNT6555 for therapy is planned for...
Global Demand of Radiopharmaceutical Market Size & Share Value Will Cross USD 11.8 Billion by 2028, with a Stellar CAGR of 10.5% Growth | Radiopharmaceutical Industry Trends & Forecast Report by Facts & Factors
11 avr. 2022 11h00 HE
|
Facts & Factors
LONDON, UK, April 11, 2022 (GLOBE NEWSWIRE) -- Facts and Factors has published a new research report titled “Radiopharmaceutical Market By Type (Therapeutic and Diagnostic), By Application...
Global Radiopharmaceuticals Market to 2030 - Featuring Cardinal Health, Curium Pharma and Siemens Healthineers Among Others
06 avr. 2022 06h23 HE
|
Research and Markets
Dublin, April 06, 2022 (GLOBE NEWSWIRE) -- The "Radiopharmaceuticals Global Market Opportunities And Strategies To 2030, By Type, Application, End-User" report has been added to...
POINT Biopharma Reports Fiscal 2021 Financial Results and Provides Business Update
25 mars 2022 08h30 HE
|
POINT Biopharma
Reported 27-patient dosimetry data from the lead-in cohort of the SPLASH trial Randomization phase of SPLASH trial ongoing, top line data expected mid-2023 Phase 1 therapeutic trial for PNT6555, the...
POINT Biopharma Confirms No Delays to SPLASH Trial Due to Recent Global Lutetium Supply Interruption
22 mars 2022 08h30 HE
|
POINT Biopharma
INDIANAPOLIS, March 22, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
Global Radiopharmaceuticals Market Analysis Report 2021: Market to Reach $8.9 Billion by 2026 - COVID-19 Presents Generational Opportunity
27 janv. 2022 04h43 HE
|
Research and Markets
Dublin, Jan. 27, 2022 (GLOBE NEWSWIRE) -- The "Radiopharmaceuticals - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global...
Global Nuclear Medicine Markets, Analysis, Forecast & Opportunities, 2016-2020 & 2021-2026
31 déc. 2021 09h33 HE
|
Research and Markets
Dublin, Dec. 31, 2021 (GLOBE NEWSWIRE) -- The "Global Nuclear Medicine Market, By Type, By Diagnostic Nuclear Medicine, By Therapeutic Nuclear Medicine, By Application, By Diagnostic Applications,...
Curium Initiates ECLIPSE, a Phase 3 Clinical Trial For Its Investigational Lu 177 PSMA I&T
27 oct. 2021 02h15 HE
|
Curium
St. Louis, MO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Curium announced today that the Company has received a Study May Proceed letter from the U.S. Food and Drug Administration (FDA) to begin its Phase 3...